Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

In corporate news, Shell (LON: SHEL) stock was down 1.4% after the energy giant, the world’s largest trader of liquefied ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Recent health news includes Donald Trump's consideration of an executive order on gas stoves, Roche's acquisition of Poseida, ...

European shares were slightly higher on Wednesday despite worries about inflation and the outlook for interest rates. The euro ...

Investing.com - European stock markets broadly retreated Wednesday, with investors cautious as they digested the region’s ...

(Alliance News) - Roche Holding AG on Wednesday said that it has completed the tender offer for all outstanding shares of Poseida Therapeutics Inc, a clinical-stage biopharmaceutical company, through ...

Discover the latest news and updates on Roche Diagnostics with insights on their Silicon Valley campus facade.

Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics , a ...